The United States has taken a significant regulatory step in the field of women’s health with the Food and Drug Administration (FDA) extending the approval of Addyi (flibanserin) to include women over the age of 65 who have gone through menopause. The medication, often referred to in the media as a “female Viagra”, is prescribed to address persistent low sexual desire associated with emotional distress, a condition known as hypoactive sexual desire disorder (HSDD).
Previously, Addyi had been authorised in the United States only for premenopausal women. The expansion of its indication marks a shift in how female sexual health is being addressed by regulators, while also reigniting longstanding scientific and ethical discussions surrounding the treatment of libido-related complaints in older women.
A controversial regulatory journey in the United States
Addyi’s path to approval has been notably complex. Before receiving initial authorisation in 2015, the FDA rejected the drug on two occasions, citing limited clinical benefit and concerns about adverse effects. The final approval came after further data review and intense public advocacy, including campaigns that framed the lack of treatments for female sexual dysfunction as a matter of gender equity in healthcare.
The drug acts on the central nervous system rather than on genital blood flow. Flibanserin modulates neurotransmitters linked to mood and motivation, increasing dopamine and noradrenaline activity while reducing serotonin levels. This mechanism reflects the understanding that sexual desire is a cognitive and emotional process, rather than a purely physiological response.
Safety concerns and modest clinical benefits
Despite the regulatory expansion in the United States, Addyi remains under strict safety warnings. The FDA requires a boxed warning — its most serious type — highlighting the risk of severe hypotension and fainting, particularly when the medication is taken alongside alcohol. Commonly reported side effects include dizziness, nausea and fatigue, which have contributed to cautious uptake since the drug entered the market.
Scientific studies published in peer-reviewed journals indicate that flibanserin can lead to statistically significant improvements in overall sexual function scores and reductions in distress related to low desire, both in premenopausal and postmenopausal women. However, these benefits are generally described as modest. Systematic reviews and meta-analyses have consistently shown that responses vary widely between individuals, limiting the predictability of outcomes in routine clinical practice.
Understanding desire after menopause
The debate surrounding Addyi highlights broader challenges in addressing sexual health after menopause. Hormonal changes, including reductions in oestrogen and testosterone, interact with psychological wellbeing, relationship dynamics and physical health. International clinical guidelines emphasise that conditions such as depression, chronic illness and relational stress must be carefully evaluated before attributing low desire to a single medical cause.
Experts in gynaecology and sexual medicine have repeatedly stressed that HSDD is difficult to define and measure. Unlike male erectile dysfunction, which can be assessed through more objective physiological markers, female sexual desire is influenced by biological, emotional and sociocultural factors. This complexity complicates both diagnosis and the interpretation of clinical trial results.
Gender equity and ongoing research
Supporters of Addyi argue that the FDA’s decision reflects progress towards gender balance in sexual health research, particularly in the United States, where pharmacological solutions for male sexual dysfunction have long been available. Critics, however, caution against oversimplifying female sexuality or equating desire with male patterns of sexual response.
Medical associations and researchers continue to call for more comprehensive studies that better reflect real-life conditions, including relationship quality, self-image and emotional intimacy — variables often excluded from clinical trials. There is broad consensus that medication, where used, should form part of a wider, individualised approach that prioritises careful clinical assessment and open patient–doctor communication.
A cautious step forward
The expanded approval of Addyi in the United States represents an important moment in the ongoing conversation about women’s health and ageing. While it offers an additional option for some postmenopausal women experiencing distressing loss of sexual desire, it also underscores the limitations of pharmacological solutions in addressing a deeply multifaceted aspect of human health.
As research continues to evolve, health professionals stress that no pill can replace comprehensive care that considers hormonal, psychological and relational dimensions. In this context, the FDA’s decision may be best viewed not as a definitive answer, but as part of a broader and still-developing effort to better understand and support female sexual wellbeing across the lifespan.